Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Profit After Tax (2022 - 2025)

Historic Profit After Tax for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to -$30.0 million.

  • Phathom Pharmaceuticals' Profit After Tax rose 6497.54% to -$30.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$274.6 million, marking a year-over-year increase of 1911.8%. This contributed to the annual value of -$334.3 million for FY2024, which is 6584.29% down from last year.
  • Per Phathom Pharmaceuticals' latest filing, its Profit After Tax stood at -$30.0 million for Q3 2025, which was up 6497.54% from -$75.8 million recorded in Q2 2025.
  • Over the past 5 years, Phathom Pharmaceuticals' Profit After Tax peaked at -$30.0 million during Q3 2025, and registered a low of -$94.3 million during Q1 2025.
  • Its 4-year average for Profit After Tax is -$62.2 million, with a median of -$55.0 million in 2022.
  • Its Profit After Tax has fluctuated over the past 5 years, first crashed by 12322.96% in 2024, then soared by 6497.54% in 2025.
  • Phathom Pharmaceuticals' Profit After Tax (Quarter) stood at -$55.0 million in 2022, then crashed by 44.55% to -$79.6 million in 2023, then rose by 6.43% to -$74.5 million in 2024, then surged by 59.74% to -$30.0 million in 2025.
  • Its last three reported values are -$30.0 million in Q3 2025, -$75.8 million for Q2 2025, and -$94.3 million during Q1 2025.